We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 59

China aims to strengthen the protection of consumers’ personal information
  • McDermott Will & Emery
  • China
  • June 6 2013

The Standing Committee of the National People's Congress recently issued a draft amendment that would update China's 20-year-old Consumer Protection


China’s merger control rules changing: MOFCOM publishes new draft regulations on remedies and simple cases
  • McDermott Will & Emery
  • China
  • April 17 2013

China's Ministry of Commerce recently issued two new draft regulations. The first provides a wider range of potential remedies to obtain the


Anti-monopoly pre-merger notification filing practice in China
  • McDermott Will & Emery
  • China
  • February 28 2009

In the past two years, there have been several major antimonopoly merger filings with the Ministry of Commerce of China (MOFCOM), including pre-merger notifications filed under the new Anti-Monopoly Law (AML


Whistleblowing in China and the United States
  • McDermott Will & Emery
  • China, USA
  • August 29 2013

Recent events in China underscore the importance of dealing effectively with whistleblowers. The Chinese Government's wide-ranging bribery and


China takes further steps to strengthen the protection of personal information
  • McDermott Will & Emery
  • China
  • August 19 2013

Recent provisions issued by China's Ministry of Industry and Information Technology underscore the country's increased emphasis on the protection of


China streamlines antitrust notification process
  • McDermott Will & Emery
  • China
  • June 27 2012

The Ministry of Commerce of China recently promulgated a new amended merger notification form along with instructions for completing the form


China improves clinical trials and speeds up drug licensing
  • McDermott Will & Emery
  • China
  • April 5 2012

With increasing investment in research and development by foreign companies in China, assuring the reliability and efficiency of the drug and device development process is a critical priority


Resale price maintenance in China: enforcement authorities imposing large fines for anti-monopoly law violations
  • McDermott Will & Emery
  • China
  • August 9 2013

Recently Shanghai High People's Court reached a decision in the first lawsuit involving resale price maintenance (RPM) since China's Anti-Monopoly


China to streamline clinical trials
  • McDermott Will & Emery
  • China
  • December 14 2011

Recently, the Chinese government issued guidelines for Phase 1 clinical drug trials in an effort to make them safer, better organized and less time-consuming


An RMB 150-million litigation in China for the abuse of a dominant market position
  • McDermott Will & Emery
  • China
  • April 24 2012

Recently, the High People’s Court of Guangdong held a public hearing for a high-profile lawsuit involving two software giants and alleged abuse of a dominant market position